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Abstract- Acute Myeloblastic Leukemia is one of the important malignancies in children. For better 
managing the prognosis of this disease, there should be enough information about common features of this 
malignancy. The aim of this study was to evaluate these common features in children with Acute 
Myeloblastic Leukemia. A total of 104 eligible children less than 15-year-old have been referred from 2007-
2011 to two referral centers for childhood malignancies. Basic epidemiological information recorded in 
checklists for each individual. Analyzes have been done by SPSS version 22. Out of patients, 57 cases were 
males (54.8%). The male/female ratio was 1.2. The mean age of patients was 6.5 ± 4.3 years. The majority 
subtypes of patients were M3, M4, non-M3, and M2, respectively. The common molecular abnormalities 
were t (15;17) and inv (16). Of patients, 19.2% had an early relapse. The mean age of relapse in patients was 
6.7 ± 3.9 years. Sixty patients (57.7%) were alive, and 44 cases (42.3%) died during or after therapy. The 
three years overall survival rate of patients was 42% in this study. According to our data, AML has the same 
frequency as compared with data from developing countries. But different epidemiological characteristic was 
a lower rate of three years overall survival in patients. These data may serve the health authorities for more 
effective environmental and preventive measurements, purposeful allocation of resources for facilitating up-
to-date diagnostic and treatment modalities, psychological support programs for respective family members 
and educational purposes. 
© 2015 Tehran University of Medical Sciences. All rights reserved.  
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Introduction 
 
The major public health issue in worldwide is 
childhood malignancies that need facilitating specialized 
centers, medical and nursing personnel and financial 
resources ( 3-1 ). One of the most frequent malignancies 
in different parts of the world with a prevalence of over 
30% of all childhood malignancies is acute leukemia ( 6-
4). Acute Lymphoblastic Leukemia (ALL) with Acute 
Myeloblastic Leukemia (AML) implies 97% of acute 
leukemia (7). Exposure to ionizing agents, certain 
chemicals, drugs and viruses, genetic defects, and 
alterations can be causative factors in etiology and 
pathogenesis of acute leukemia (8), and environmental 
and socioeconomic conditions are well known 
predisposing importance (9). As well, recognized risk 
factors for acute leukemia incidences are cancer history 
in the family and siblings of children suffering from 
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leukemia with a fourfold risk (10-13). 
AML is a type of heterogeneous acute leukemia, 
which is less frequent than ALL (20 versus 80%) and 
characterized by rapid progression (14-20). The 
incidence of pediatric AML is 5-7 cases per million 
annually (21). Childhood AML has a varied incidence 
rate with a peak in the first two years of life and has a 
similar frequency in male and female (21-23).  
According to official reports, cancer ranks after car 
accidents and coronary heart disease as the third cause 
of death in Iran (1) and pediatric cancers rank as the 
sixth group of common malignancies in Iran (17-19). 
Literature and reviews show that survival of childhood 
AML is lower than ALL, and their survival rate has 
improved during recent decades. In children less than 15 
years old, the overall survival rate of AML is between 
60-70% (14).  
MAHAK Pediatric Cancer Treatment and Research 
Center (MPCTRC) and Children’s Medical Center 
(CMC) are the main national referral hospitals for 
childhood malignancies. Due to a large number of 
referrals to these centers, data compiled can be 
considered as reference for any issues related to national 
health strategies and policies to facilitate and optimize 
medical services for pediatric malignancies.  
The purpose of this study was to evaluate the 
common features of children with AML, who admitted 
to MPCTRC and CMC for diagnosis and treatment. 
According to being like a double center study of this 
manuscript, no investigator could claim about the 
representativeness of his/her patients to the national 
pattern.  
 
Materials and Methods 
 
The study group comprised 104 eligible patients with 
AML, registered at MPCTRC and CMC since April 
2007 to April 2011. Patients treated at other centers or 
referred for consultation were excluded from this study. 
In the same time span, a total number of eligible and 
admitted patients with childhood leukemia to MPCTRC 
and CMC were 545 cases. Diagnosis and treatment of 
AML were based on clinical manifestations, 
morphological criteria according to FAB (French-
American-British) (14) classification, flow cytometry, 
and cytogenetic aberrations. Treatment modalities were 
AML BFM (Berlin-Frankfurt-Munster) - protocol 
(1983) (14).  
 
Epidemiological Evaluation 
A comprehensive questionnaire has been assigned 
for each patient. It included information about sex, age 
at diagnosis, immunophenotyping, molecular 
abnormalities, date of last treatment, date of the last 
visit, and etc.  
 
Analysis  
Data was analyzed by SPSS version 22, with 
confidence intervals of 95%. Kolmogorov-Smirnov test 
was used for consideration the distribution of normal or 
abnormal patterns in variables, Chi-square for 
parametric and Spearman method for non-parametric 
data, respectively. And also for comparing two means 
we used t-test.  
 
Results 
 
There were 545 patients with childhood leukemia, 
who registered at MPCTRC and CMC from April 2007 
to April 2011. Out of admitted patients, 441 (80.9%) had 
acute lymphoblastic leukemia, and 104 (19.1%) had 
AML. Those 104 eligible patients with AML and less 
than 15 years old comprised the study group.  
Out of enrolled patients, 57 cases were males 
(54.8%). Patients were categorized according to their 
age at diagnosis into four groups: <1 year (n=10, 9.6%), 
1-5 years (n=36, 34.6%), 5-10 years (n=28, 26.9%), and 
over 10 years old (n=30, 28.9%). The mean age at 
diagnosis was 6.5 ± 4.3 years (range 1 month to 15 
years). The M/F ratio was 1.2.  
The Kolmogorov-Smirnov test has not demonstrated 
any comparable age distribution pattern in patients. The 
analysis by Spearman test has not revealed any 
significant relation between patient’s age and sex at 
diagnosis in the study group.  
Out of 104 patients with AML, the majority had M3 
(n=21, 20.2%) followed by M4 (n=20, 19.2%), by non-
M3 (n=19, 18.3%) and by M2 (n=12, 11.5%). Other 
types as biphenotype (n=7), M5 (n=6), M1 (n=5), M7 
(n=3), M6 (n=2) and M0 (n=1) was reported 
respectively in considered patients. Unfortunately, 8 
cases were as undifferentiated individuals.   
Molecular abnormalities were evaluated according to 
genetic laboratory test’s reports. Twenty patients 
(19.2%) showed positive reports for t(15;17) (n=6, 
30%), inversion (n=5, 25%), mosaicism with deletion 
(n=2, 10%), t(8;21), t(6;11), hyperdiploidy, mosaicism 
with translocation, mosaicism with monosomy, trisomy 
8 and gene deletion  (n=1,5%) respectively. 
During the treatment,20 cases (19.2%) had an early 
relapse. The mean age of relapse in patients was 6.7 ± 
3.9 years. Chi-square test showed a significant relation 
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between age and relapse in enrolled patients (P-
value<0.05).  
The last status of patients showed that 60 patients 
(57.7%) were alive, and 44 cases (42.3%) died during or 
after therapy. Out of alive individuals, 16 patients 
(26.7%) were lost to follow-up at MPCTRC and CMC 
because of referring to other centers for continuing their 
treatment. The three years overall survival rate of 
patients was 42% in this study. The mean time of 
survival was 16 months (Figure 1).  
 
 
Figure 1. Three years survival rate in enrolled patients 
 
 
Discussion 
 
AML a type of malignancy affecting the myeloid 
cell line causes overproduction of abnormal blast cells. 
The aim of this study was an evaluation of the common 
features of AML patients, referred and admitted to 
MPCTRC (MAHAK’s Pediatric Cancer Treatment and 
Research Center) and CMC (Children’s Medical 
Center) for diagnostic procedures, treatment, and 
follow-up. MAHAK as an NGO to support children 
suffering from cancer has started since early 1991. It 
has social and supportive activities in pediatric 
hematology and oncology departments in academic 
centers in Tehran. The estimated annual cancer 
incidence in Iran is 150 per 100.000 in children aged 0-
15 years, meaning 3.000-3.500 new cancers, which is 
higher than reported from developed countries, 
although some reports indicate an increasing cancer 
incidence in these countries (19).  
The prevalence of acute leukemia in most part of 
the world is over 30% of all childhood malignancies 
( 3-2 ). According to MPCTRC and CMC data, ALL 
comprised 80.9% and AML 19.1% of acute leukemia, 
which is in concordance with reported reports in the 
literature ( 8-2 ).  
The incidence rate of AML in males was higher than 
females (nearly 1.2 fold) in patients. According to data, 
in AML group less than five years old the resemblance 
incidence of sex distribution was revealable. These data 
has similarity to other literature (3-5, 7-15) . The peak 
age for enrolled patients being 1-5 years (the mean 
age=6.5 ± 4.3 years). In this study, the mean age at 
presentation was similar as reported in the literature (21).  
Universal FAB classification in patients with AML 
reported that types of M5 and M7 are more common in 
early age groups of children, and other subtypes will 
see in the elder age groups of patients in this study the 
patterns of subtypes in enrolled patients were similar to 
reported reports.  
Additional information that obtained from more 
laboratory techniques regards to genetic make-up of 
AML cells. Certain cytogenetic changes associated 
with AML subtypes. Children with AML malignancy 
have the t (15,17) and inv (16) as the most genetic 
abnormality in their cell line. In this study, these two 
molecular abnormalities were more revealed in patients 
and other genetic disorders were as reported ones in 
acute leukemia.  
Gaynon and coworkers, Azarm and et al., in 
different studies concluded that nearly 30% of patients 
with AML encounter with relapse during their 
treatment. There was a significant relation between sex 
and age in relapsed AML patients in their findings. In 
this study, the analysis was in concordance with their 
findings of relapse in childhood AML.  
Overall survival (OS) rates have improved over the 
past decades in patients with childhood AML. Five 
years survival rates in children are 55-65% at present. 
In the current study, the three years survival rate of 
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patients was 42% as it will decrease for five years 
survival rate. One of the probabilities of this lower 
survival rate can be the low number of considered 
patients as it was only a double center study. For 
achieving better conclusion through this subject, more 
evaluation should be considered for patients with 
childhood AML in Iran.  
In conclusion, the presented data demonstrate the 
same frequency of basically information in patients 
with childhood AML. However, apart from low overall 
survival rate in patients, higher male affliction and high 
mean age at presentation in 1 to 5 years old age group, 
there are significant differences in terms of subtypes 
and genetic abnormalities as compared to reports from 
developed countries ( 6-5 ).  
By designing advanced projects on patients with 
childhood acute leukemia, health authorities in other 
referral childhood centers can utilize epidemiological 
data compiled at MPCTRC and CMC as the basis for 
their medical care planning and various informative 
and educational programs. Furthermore, our data are 
accessible for academic research institutions.  
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